Novartis to Acquire Regulus in $1.7 Billion Deal
In This Article:
With the merger, the Swiss pharmaceutical company aims to bring to more patients farabursen, a kidney-disease treatment developed by Regulus.
Oops, something went wrong
Unlock stock picks and a broker-level newsfeed that powers Wall Street.
With the merger, the Swiss pharmaceutical company aims to bring to more patients farabursen, a kidney-disease treatment developed by Regulus.